Korean Post-marketing Surveillance for Orencia
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 08 Nov 2017 Results (n=341) assessing DAS28P as a predictor of EULAR response to abatacept in patients with RA, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 08 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 04 Aug 2014 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 according to ClinicalTrials.gov record.